Market Intelligence Report

In Vivo CAR-T Market Intelligence Report

Strategic landscape analysis of delivery platforms, competitive positioning and deal activity

A strategy-oriented review of why in vivo CAR-T is attracting renewed interest, where delivery technologies are differentiating and how recent partnerships, financings and acquisitions are shaping the field.

Last updated

April 28, 2026

Audience

Biopharma strategy, business development, competitive intelligence and investor-facing teams

Scope

Publicly visible developers, transactions and financings

This report is based on publicly available information as of April 28, 2026. Pipeline status, partnership terms, financing details and company positioning may change as new disclosures emerge.

Key takeaways One-page summary

Bottom line

In vivo CAR-T is not yet a proven replacement for ex vivo CAR-T. Its strategic importance lies in its potential to shift CAR-T from a complex, patient-specific manufacturing model toward a more scalable, drug-like delivery model if targeted in-body immune-cell programming can be shown to work safely and durably.

Loading local report...